Novel LipoAvail® Liposomal NMN Elevates 6X NAD+

Overview

Effepharm

Liposomal technology encapsulates active ingredients within liposomes, mimicking intestinal cell membranes for improved absorption and bioavailability.

LipoAvail® NMN, Uthever® NMN powered by LipoAvail® Liposomal Technology, offers the only lab-validated liposomal NMN on the market. After 14 consecutive days, the LipoAvail® NMN group demonstrated 1.74 times higher NAD+ levels in mouse liver tissue and 5.95 times higher NAD+ levels in mouse skeletal muscle compared to the regular NMN group.

Download the Liposome White Paper and catalog for more liposomal product like liposomal VC and glutathione.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now

Related Topics

IngredientsHealth

Latest Content

Related Resources

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

Paid for by Effepharm Ltd

White Paper

On 11th May 2026, EFSA officially published a positive scientific opinion on EffePharm’s β-NMN as a novel food. This is the first-ever EU official safety endorsement for NMN. UTHEVER® is the 1st NMN ingredient brand to receive EFSA’s positive opinion.

Uthever® NMN: Novel Food Approval Nearing Final Stage

Uthever® NMN: Novel Food Approval Nearing Final Stage

Paid for by Effepharm Ltd

White Paper

One Step Away from EU Market Compliance for NMN. The official positive opinion of Novel Food is expected to be published shortly, which means Uthever® NMN will be the first compliant ingredient.

Supplier Info Centre

Effepharm-Ltd.jpg

For more product information visit Effepharm Ltd.